Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-09 pm EDT			5-day change	1st Jan Change
113.24 ^USD	+1.96%		+1.55%	+22.59%

05:40am	Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	MT
Jul. 09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE

Highlights

Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	05:40am	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Gilead finalizes agreement with global fund to accelerate access to Lenacapavir	Jul. 09	RE
Tariff Drama, Minimal Market Reaction	Jul. 09
Gilead Sciences, Inc. Finalizes Agreement with the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for Up to Two Million People in Primarily Low- and Lower- Middle-Income Countries	Jul. 09	CI
Assembly Biosciences Doses First Participant in Phase 1B Portion of Phase 1A/B Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179	Jun. 30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	Jun. 30	RE
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Assembly Biosciences Reports Positive Topline Results from Phase 1B Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B	Jun. 25	CI
Gilead Sciences, Inc. and Kymera Therapeutics, Inc. Enter into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders	Jun. 25	CI
Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program	Jun. 25	MT
Global markets live: Microsoft, Gilead Sciences, Ford Motor, Vodafone, UBS…	Jun. 19
US FDA approves Gilead's twice-yearly injection for HIV prevention	Jun. 18	RE
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis	Jun. 18	CI
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention	Jun. 18	RE
Ex-dividend day	Jun. 12	FA
US FDA pauses Gilead trials testing experimental HIV pill combination	Jun. 10	RE
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials	Jun. 10	MT
Gilead Says FDA Placed Clinical Hold On HIV Treatment Trials Of GS-1720 And/Or GS-4182	Jun. 10	RE
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination	Jun. 10	RE
Gilead's CAR-T cell therapy shows promise in deadly brain cancer	Jun. 01	RE
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer	May. 31	CI
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy	May. 23	CI
Sector Update: Health Care Stocks Softer Late Afternoon	May. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Highlights

Filters